Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 5/2009

01-10-2009 | Original Article

Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group

Authors: Pasquale Comella, Vito Lorusso, Luigi Maiorino, Rossana Casaretti, Michele Cannone, Bruno Massidda, Carlo Putzu, Silvana Leo, Mario Roselli, Sergio Mancarella, Sergio Palmeri, Ettore Greco, Giacomo Vessia, Claudia Sandomenico, Luca Franco

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2009

Login to get access

Abstract

Purpose

This phase II trial assessed the tolerability and efficacy of a triplet of oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer.

Methods

Patients with unresectable or metastatic gastric cancer, unexposed to palliative chemotherapy, received oxaliplatin 85 mg/m2 iv and irinotecan 150 mg/m2 iv on day 1, 6S-folinic acid 250 mg/m2 iv and fluorouracil 750 mg/m2 iv on day 2, every 2 weeks. Response rate (RR) was assessed after a minimum of four cycles, and treatment continued up to 12 cycles.

Results

Sixty-three patients were treated, with a median of eight (range 1–12) cycles/patient. Two complete and 19 partial responses were registered (RR 33% [95% CI, 22–46%]). Median progression-free survival was 7.5 (95% CI, 5.6–9.4) months, and median overall survival was 12.1 (95% CI, 10.8–13.4) months. Most common grade ≥3 toxicities were neutropenia (59%), febrile neutropenia (7%), vomiting (20%), and diarrhoea (10%). All-grade neurotoxicity affected 33% of patients.

Conclusions

Oxaliplatin, irinotecan, and fluorouracil/folinic acid administered every 2 weeks are safe and active in advanced gastric cancer.
Literature
1.
Wohrer SS, Radere M, Hejna M (2004) Palliative chemotherapy for advanced gastric cancer. Ann Oncol 15:1585–1595PubMedCrossRef
2.
Van Cutsem E, Van de Velde C, Roth A et al (2008) Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)—Gastrointestinal Cancer Group. Eur J Cancer 44:182–194PubMedCrossRef
3.
Wagner AD, Grothe W, Haerting J et al (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903–2909PubMedCrossRef
4.
Cunningham C, Jost LM, Purkalne G, Oliveira J (2005) ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of gastric cancer. Ann Oncol 16:22–23CrossRef
5.
Webb A, Cunningham D, Scarffe JH et al (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261–267PubMed
6.
Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36–46PubMedCrossRef
7.
Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991–4997PubMedCrossRef
8.
Köhne CH, Catane R, Klein B et al (2003) Irinotecan is active in chemonaive patients with metastatic gastric cancer phase II multicentric trial. Br J Cancer 89:997–1001PubMedCrossRef
9.
Farhat FS (2007) A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer. Med Oncol 24:137–146PubMedCrossRef
10.
Moehler M, Haas U, Siebler J et al (2003) Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (IFL) in patients with advanced gastric cancer. Anticancer Drugs 14:645–650PubMedCrossRef
11.
Assersohn L, Brown G, Cunningham D et al (2004) Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol 15:64–69PubMedCrossRef
12.
Bouché O, Raoul JL, Bonnetain F et al (2004) Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803. J Clin Oncol 22:4319–4328PubMedCrossRef
13.
Kim ST, Kang WK, Kang JH et al (2005) Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer. Br J Cancer 23:1850–1854CrossRef
14.
Dank M, Zaluski J, Barone C et al (2008) Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to Cisplatin combined with 5-fluorouracil in chemotherapy naïve patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 19:1450–1457PubMedCrossRef
15.
Louvet C, André T, Tigaud JM et al (2002) Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 20:4543–4548PubMedCrossRef
16.
Al-Batran SE, Atmaca A, Hegewisch-Becker S et al (2004) Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 22:658–663PubMedCrossRef
17.
Chao Y, Yeh KH, Chang CJ et al (2004) Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. Br J Cancer 91:453–458PubMedCrossRef
18.
De Vita F, Orditura M, Matano E et al (2005) A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 92:1644–1649PubMedCrossRef
19.
Lordick F, Lorenzen S, Stollfuss J et al (2005) Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. Br J Cancer 93:190–194PubMedCrossRef
20.
Kim DY, Kim JH, Lee SH et al (2003) Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer. Ann Oncol 14:383–387PubMedCrossRef
21.
Al-Batran S-E, Hartmann JT, Probst S et al (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26:1435–1442PubMedCrossRef
22.
Placencia C, Taron M, Abad A, Rosell R (2000) Synergism of oxaliplatin (OXA) with either 5-fluorouracil (5FU) or topoisomerase I inhibitor in sensitive and 5FU-resistant colorectal cancer cell lines is independent of DNA-mismatch repair and p53 status. Proc Am Soc Clin Oncol 19:204a (Abstr 793)
23.
Fischel J-L, Etienne M-C, Formento P, Milano G (1998) Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data. Clin Cancer Res 4:2529–2535PubMed
24.
Tanaka R, Ariyama H, Qin B et al (2005) Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro. Oncol Rep 14:683–688PubMed
25.
Souglakos J, Syrigos K, Potamianou A et al (2004) Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial. Ann Oncol 15:1204–1209PubMedCrossRef
26.
Wöll E, Kühr T, Eisterer W (2008) Biweekly oxaliplatin and irinotecan chemotherapy in advanced gastric cancer. a first-line multicenter phase II trial of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT). Anticancer Res 28:2901–2905PubMed
27.
Comella P, Casaretti R, De Rosa V et al (2002) Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies. Ann Oncol 13:1874–1881PubMedCrossRef
28.
Comella P, Massidda B, Palmeri S et al (2006) Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer. Anticancer Drugs 7:985–992CrossRef
29.
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214PubMedCrossRef
30.
Lévi F, Misset JL, Brienza S et al (1992) A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 69:893–900PubMedCrossRef
31.
Simon R (1989) Optimal two stage design for phase II clinical trials. Control Clin Trials 10:1–10PubMedCrossRef
32.
Kaplan ES, Meier P (1958) Non parametric estimation for incomplete observations. J Am Stat Assoc 53:557–580CrossRef
33.
Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ (2004) Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer—pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 22:2395–2403PubMedCrossRef
34.
Lee J, Kang WK, Kwon JM et al (2007) Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma. Ann Oncol 18:88–92PubMedCrossRef
35.
Bajetta E, Celio L, Ferrario E et al (2007) Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. Ann Oncol 18:1810–1816PubMedCrossRef
36.
Fornaro L, Masi G, Bursi S (2008) A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer. Cancer Chemother Pharmacol, Oct 7. (Epub ahead of print)
37.
Maroun JA, Jonker D, Cripps C, Goel R, Lister D, Chiritescu J (2007) Encouraging results from a phase I study of capecitabine, oxaliplatin and irinotecan as first-line therapy in patients with metastatic colorectal cancer (MCRC). J Clin Oncol, 2006 ASCO Annual Meeting Proceedings, Part I, vol 25, No. 18S (June 20 Supplement), 4086
Metadata
Title
Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group
Authors
Pasquale Comella
Vito Lorusso
Luigi Maiorino
Rossana Casaretti
Michele Cannone
Bruno Massidda
Carlo Putzu
Silvana Leo
Mario Roselli
Sergio Mancarella
Sergio Palmeri
Ettore Greco
Giacomo Vessia
Claudia Sandomenico
Luca Franco
Publication date
01-10-2009
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-009-0938-4

Other articles of this Issue 5/2009

Cancer Chemotherapy and Pharmacology 5/2009 Go to the issue

Original Article

Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4′-methanol-bisbenzonitrile in vitro

Original Article

The acute effects of CMF-based chemotherapy on maxillary periodontal microcirculation

Original Article

Chemoprotection and enhancement of cancer chemotherapeutic efficacy of cyclophosphamide in mice bearing Ehrlich ascites carcinoma by diphenylmethyl selenocyanate

Editorial

Fotemustine and recurrent glioblastoma: possible new opportunities for an old drug

Original Article

In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer

Original Article

Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits